Naples, Italy: The administration of the non-psychotropic cannabinoid cannabigerol (CBG) possesses potent anti-colon cancer activities and inhibits cancerous tumor growth, according to preclinical data published online ahead of print in the journal Carcinogenesis. Colorectal cancer is the third most common cancer in men and the second most common cancer in women worldwide.
Italian researchers at the University of Naples assessed the effects of CBG on colon tumorigenesis in vitro and in vivo. Investigators reported that the compound promoted apoptosis (cancer cell death) and reduced cell growth in colorectal cancer cells. CBG dosing also inhibited an experimental model of colorectal tumor growth in animals.
Authors concluded: "Our data show that the non-psychotropic cannabis ingredient cannabigerol inhibits the growth of colorectal cancer cells ... and hinders the development and growth of colon carcinogenesis in vivo. ... [W]e hypothesize that CBG may be a promising anti-colorectal cancer therapeutic agent, both for prevention and as a curative medicine."
Cannabinoids and endocannabinoids have been shown both independently and adjunctively to possess anti-cancer activity in preclinical models, halting the proliferation of glioma cells, breast carcinoma, lung carcinoma, and lymphoma, among other cancer cell lines.
For more information, please contact Paul Armentano, NORML Deputy Director, at: firstname.lastname@example.org. Full text of the study, "Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a cannabis-derived non-psychotropic cannabinoid," appears in Carcinogenesis.